Taysha Gene Therapies Advances the Development of TSHA-102 for Rett Syndrome - Analysts see up to 133% Price Potential

On May 28, Taysha Gene Therapies (TSHA) reported significant progress in the development of TSHA-102, a gene therapy treatment for Rett syndrome. The Phase 1/2 studies, known as REVEAL, were conducted in two parts: Part A focused on dose finding, while Part B aims to evaluate the efficacy and safety in an expanded patient group. In February 2025, the company reported that TSHA-102 was well tolerated in both low and high doses, with no serious treatment-related side effects or dose-limiting toxicities observed among pediatric, adolescent, and adult...